ECSP13012679A - Composiciones farmacéuticas que comprenden alisporivir - Google Patents

Composiciones farmacéuticas que comprenden alisporivir

Info

Publication number
ECSP13012679A
ECSP13012679A ECSP13012679A ECSP13012679A EC SP13012679 A ECSP13012679 A EC SP13012679A EC SP13012679 A ECSP13012679 A EC SP13012679A EC SP13012679 A ECSP13012679 A EC SP13012679A
Authority
EC
Ecuador
Prior art keywords
alisporivir
pharmaceutical compositions
based pharmaceutical
provides lipid
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Bertrand Sutter
Frank Stowasser
Elisabete Goncalves
Karin Rapp
Bjoern Trupp
Sebastian Chabaut
Julien Thorens
Original Assignee
Novartis Ag
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Debiopharm Sa filed Critical Novartis Ag
Publication of ECSP13012679A publication Critical patent/ECSP13012679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

La invención proporciona composiciones farmacéuticas basadas en lípido, las cuales comprenden alisporivir.
ECSP13012679 2010-12-13 2013-06-13 Composiciones farmacéuticas que comprenden alisporivir ECSP13012679A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42249910P 2010-12-13 2010-12-13
IB2011000319 2011-02-18
IB2011000653 2011-03-25
PCT/EP2011/072463 WO2012080176A2 (en) 2010-12-13 2011-12-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ECSP13012679A true ECSP13012679A (es) 2013-08-30

Family

ID=45346477

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012679 ECSP13012679A (es) 2010-12-13 2013-06-13 Composiciones farmacéuticas que comprenden alisporivir

Country Status (33)

Country Link
US (2) US20140005123A1 (es)
EP (1) EP2651396B1 (es)
JP (2) JP6259288B2 (es)
KR (1) KR101928589B1 (es)
CN (2) CN103282022A (es)
AR (1) AR084235A1 (es)
AU (3) AU2011344331A1 (es)
BR (1) BR112013014606A2 (es)
CA (1) CA2819167C (es)
CL (1) CL2013001684A1 (es)
CO (1) CO6761388A2 (es)
CY (1) CY1119468T1 (es)
DK (1) DK2651396T3 (es)
EC (1) ECSP13012679A (es)
ES (1) ES2643135T3 (es)
HR (1) HRP20171485T1 (es)
HU (1) HUE036784T2 (es)
IL (1) IL226554A (es)
JO (1) JO3337B1 (es)
LT (1) LT2651396T (es)
MA (1) MA34709B1 (es)
MX (1) MX351667B (es)
MY (1) MY165088A (es)
NZ (1) NZ610950A (es)
PE (1) PE20140104A1 (es)
PL (1) PL2651396T3 (es)
PT (1) PT2651396T (es)
RU (1) RU2639482C2 (es)
SG (2) SG190894A1 (es)
SI (1) SI2651396T1 (es)
TW (1) TWI599368B (es)
WO (1) WO2012080176A2 (es)
ZA (1) ZA201303721B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
PT2651939E (pt) 2010-12-13 2015-08-04 Array Biopharma Inc Compostos n-(1h-indazol-4-il)imidazo[1,2-a]piridina-3- carboxamida substituídos enquanto inibidores de tirosina quinase de receptores de tipo iii
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
FR2697040B1 (fr) 1992-10-21 1994-12-30 Ind Entreprise Elément de protection contre le bruit et son utilisation.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
CA2331640A1 (en) * 1998-05-07 1999-11-11 Elan Corporation Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
BR9911724A (pt) * 1998-07-01 2001-03-20 Debiopharm Sa Ciclosporina que tem um perfil de atividade melhorado
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
SI1793844T1 (sl) * 2004-10-01 2011-05-31 Debiopharm Sa Uporaba (d-meala)3-(etval)4-ciklosporina za zdravljenje infekcije s hepatitisom c
JP2008525459A (ja) 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ処置用組成物
GB0504950D0 (en) 2005-03-10 2005-04-20 Novartis Ag Organic compositions
EP2355837A1 (en) 2008-11-06 2011-08-17 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير

Also Published As

Publication number Publication date
EP2651396B1 (en) 2017-07-12
AU2011344331A1 (en) 2013-07-11
JP2018027949A (ja) 2018-02-22
CL2013001684A1 (es) 2014-01-10
JO3337B1 (ar) 2019-03-13
US20140005123A1 (en) 2014-01-02
TWI599368B (zh) 2017-09-21
MA34709B1 (fr) 2013-12-03
US20160367624A1 (en) 2016-12-22
NZ610950A (en) 2015-07-31
JP6259288B2 (ja) 2018-01-10
US10188696B2 (en) 2019-01-29
SG10201509833YA (en) 2016-01-28
MY165088A (en) 2018-02-28
JP2014503520A (ja) 2014-02-13
RU2013132543A (ru) 2015-01-20
CY1119468T1 (el) 2018-03-07
MX351667B (es) 2017-10-24
CN103282022A (zh) 2013-09-04
DK2651396T3 (en) 2017-10-23
CO6761388A2 (es) 2013-09-30
SI2651396T1 (sl) 2017-11-30
MX2013006525A (es) 2013-08-01
BR112013014606A2 (pt) 2017-06-06
HRP20171485T1 (hr) 2017-11-17
ZA201303721B (en) 2014-04-30
AU2016201053A1 (en) 2016-03-10
ES2643135T3 (es) 2017-11-21
RU2639482C2 (ru) 2017-12-21
CN105125489A (zh) 2015-12-09
CN105125489B (zh) 2019-04-16
TW201306859A (zh) 2013-02-16
PL2651396T3 (pl) 2017-12-29
AR084235A1 (es) 2013-05-02
WO2012080176A3 (en) 2012-08-09
AU2017245296A1 (en) 2017-11-02
CA2819167C (en) 2019-12-31
SG190894A1 (en) 2013-07-31
PE20140104A1 (es) 2014-02-04
HUE036784T2 (hu) 2018-08-28
PT2651396T (pt) 2017-10-18
CA2819167A1 (en) 2012-06-21
LT2651396T (lt) 2017-09-25
KR101928589B1 (ko) 2018-12-12
KR20140018858A (ko) 2014-02-13
AU2016201053B2 (en) 2017-07-13
EP2651396A2 (en) 2013-10-23
IL226554A (en) 2017-12-31
WO2012080176A2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34817A (es) Tienopirimidinas
UY34824A (es) Nucleósidos de espirooxetano de uracilo
UY4282Q (es) Caja de transmisión
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
UY34654A (es) Inhibidores de la beta-secretasa
TR201909271T4 (tr) Testosteron formülasyonları.
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
UY33906A (es) Composiciones herbicidas que comprenden topramezona
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη
UY34677A (es) Imidazopiridazinas sustituidas
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
MX2013000539A (es) Nuevas formulaciones de analogos 14-epi de la vitamina d.
CR11628A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSUAL If Y DE UN BETA-BLOQUEANTE
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112013016029A2 (pt) composição farmacêutica de fosfomicina.
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
CL2012000641S1 (es) Lavamanos.
TN2011000372A1 (fr) جهاز مراقبة وتحكم في استهلاك المياه